The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

- ETX-636 advanced to the clinic following preclinical observations showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα WALTHAM, Mass., July 01, 2025 ...

WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and ...

PI3Kα inhibitors are approved to treat certain cancers with PIK3CA mutations, but resistance often develops during treatment. Researchers have now identified additional cancer mutations that arise to ...

Deal terms include $2B upfront plus >$1B milestones for SNV4818 via Pikavation acquisition, with expected closing in 1H 2026. Mutant-selective PI3Kα inhibition seeks to address ~40% PIK3CA-mutant ...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

Researchers from Scorpion Therapeutics Inc. presented the discovery and preclinical evaluation of a novel mutant-selective, allosteric phosphoinositide 3-kinase α (PI3Kα) inhibitor, STX-478. In vitro, ...

To design drugs that stall the growth of aggressive cancers, it helps to know the structures of the proteins that are revving the cancers' engines. In a series of three papers published in Proceedings ...

Lori Friedman was sitting in her office at Genentech when her colleague Kyung Song walked in with a Western blot gel and a chemical biology conundrum. “I can’t find where the protein is going. It’s ...